Altre lingue Alnylam Pharmaceuticals, Inc. Börse Stuttgart

Azioni

DUL

US02043Q1076

Mercato chiuso - Börse Stuttgart Altri mercati azionari 21:22:02 16/07/2024			Variaz. 5gg	Var. 1 gen.
229,9 ^EUR	-2,75%		+0,47%	+34,62%

15/07	L'insider di Alnylam Pharmaceuticals ha venduto azioni per un valore di 1.851.273 dollari, secondo un recente deposito SEC	MT
26/06	L'insider di Alnylam Pharmaceuticals ha venduto azioni per un valore di 370.747 dollari, secondo un recente deposito SEC	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Alnylam Pharmaceuticals Insider Sold Shares Worth $1,851,273, According to a Recent SEC Filing	15/07
Jerome Powell did it again	03/07
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU : Alphabet, Nike, Nvidia, Tesla, Starbucks...	03/07
ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks...	03/07
Alnylam Pharmaceuticals Insider Sold Shares Worth $370,747, According to a Recent SEC Filing	26/06
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,917,475, According to a Recent SEC Filing	26/06
Alnylam Pharmaceuticals Insider Sold Shares Worth $485,773, According to a Recent SEC Filing	26/06
Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing	26/06
Industry Leader John Maraganore, Ph.D., Joins Cybrexa Therapeutics as Strategic Advisor	26/06
Sector Update: Health Care Stocks Ease Late Afternoon	25/06
Alnylam Pharmaceuticals Shares Rise as Heart Disease Candidate Meets Primary Endpoint in Late-Stage Study	25/06
Out with AI, in with defensive stocks	25/06
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU : Capri Holdings, Adobe, Broadcom, Celanese, Admiral...	25/06
ANALYST RECOMMENDATIONS : Capri Holdings, Adobe, Broadcom, Celanese, Admiral...	25/06
RXO, Alnylam Pharmaceuticals rise; ResMed, Sonoco Products fall, Monday, 6/24/2024	24/06
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	24/06
Top Midday Gainers	24/06
Alnylam Pharmaceuticals : HELIOS-B Topline Results Transcript	24/06
Alnylam Pharmaceuticals : HELIOS-B Topline Results	24/06
Los resultados del fármaco de Alnylam Pharmaceutical se consideran el "mejor escenario posible" -- Market Talk	24/06

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Alnylam Pharmaceuticals, Inc. Börse Stuttgart

Azioni

DUL

US02043Q1076

Altre lingue

Filtri